Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer

PURPOSE: Few patients with metastatic triple-negative breast cancer (mTNBC) benefit from immune checkpoint inhibitors (ICIs). Based on immunotherapy response correlates in other cancers, we evaluated whether high tumor mutational burden (TMB) ≥10 nonsynonymous mutations/megabase and PTEN alterations...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Barroso-Sousa, Romualdo, Keenan, Tanya E., Pernas, Sonia, Exman, Pedro, Jain, Esha, Garrido-Castro, Ana C., Hughes, Melissa, Bychkovsky, Brittany, Umeton, Renato, Files, Janet L., Lindeman, Neal I., MacConaill, Laura E., Hodi, F. Stephen, Krop, Ian E., Dillon, Deborah, Winer, Eric P., Wagle, Nikhil, Lin, Nancy U., Mittendorf, Elizabeth A., Van Allen, Eliezer M., Tolaney, Sara M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269810/
https://ncbi.nlm.nih.gov/pubmed/32019858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3507
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados